A single daily pill slashed “bad” cholesterol by 60% in high-risk patients, potentially revolutionizing heart disease prevention without needles—what will this mean for millions dodging heart attacks?
Story Snapshot
- Enlicitide, an oral PCSK9 inhibitor from Merck, cut LDL cholesterol by 60% at 24 weeks and sustained 55-60% reductions at 52 weeks in statin-treated patients.
- Phase 3 CORALreef Lipids Trial involved over 2,900 high-risk individuals with atherosclerosis, published February 4, 2026, in the New England Journal of Medicine.
- No major safety issues emerged; side effects matched placebo, with empty-stomach dosing required.
- FDA fast-tracks review; ongoing outcomes trial tests heart attack and stroke prevention in 14,000 patients.
- Targets the 50% of high-risk patients failing to hit LDL goals below 70 mg/dL despite maximum statins.
CORALreef Trial Delivers Breakthrough LDL Reductions
Merck’s enlicitide targeted PCSK9 protein in the phase 3 CORALreef Lipids Trial. Researchers enrolled 2,900 patients with atherosclerotic cardiovascular disease or equivalents already on statins. At 24 weeks, enlicitide reduced LDL by 60% versus a 3-9% placebo rise. Follow-up at 52 weeks held reductions at 55-60%. Non-HDL dropped 53%, ApoB 50%, and Lp(a) 28%. Dr. Ann Marie Navar at UT Southwestern led the study, calling it the most effective oral LDL cutter since statins.
Enlicitide Outpaces Statins and Matches Injectables
Statins like Lipitor block liver cholesterol production since 1987 but leave half of high-risk patients above LDL targets of 55-70 mg/dL. Injectable PCSK9 inhibitors such as evolocumab, approved in 2015, achieve similar 50-60% drops by boosting liver LDL clearance. Yet injections limit uptake to under 10% of eligible patients due to hassle and cost. Enlicitide delivers equivalent power in pill form. Patients took it on an empty stomach daily. Seventy percent hit at least 50% LDL drop plus under 70 mg/dL.
Key Stakeholders Drive Development and Approval
Merck & Co. sponsored the trial and funds a 14,000-patient outcomes study tracking heart attacks, strokes, and deaths. Dr. Ann Marie Navar oversaw operations, stressing population-wide prevention potential. The FDA granted fast-track priority review using a voucher for rapid processing. Cardiologists like Navar position as early adopters. Insurers will weigh costs against injectables, which have dropped but remain high. Merck eyes the $20 billion cholesterol market.
Power dynamics favor FDA as gatekeeper. Merck provides funding and data, while academics like Navar ensure credibility.
Implications Reshape Cardiovascular Care
Short-term, FDA approval could launch enlicitide soon, improving adherence for injection-averse patients with familial hypercholesterolemia or atherosclerosis. Long-term success in outcomes trials promises fewer events, cutting heart disease, America’s top killer. Economic shifts favor Merck market gains and lower system costs. Socially, it eases burden on underserved groups. Industry disruption spurs more oral PCSK9 rivals, building on statins-plus-add-on strategies.
Experts like Dr. William Boden praise compelling evidence matching injectables but urge outcomes data. Navar highlights transformation for those under 50% goal attainment. Safety equaled placebo at 10-12% serious events. Caveats include no hard event proof yet, real-world untested status, and dosing rules. Precedents from injectable trials like FOURIER support lipid drops translating to benefits.
Sources:
Cholesterol Levels Slashed by 60% in Promising New Pill Trial
The Cholesterol Data That Didn’t Fit the Narrative
Experimental Pill Slashes Bad Cholesterol Levels
Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor
New Pill Slashes Bad Cholesterol by 60%
